for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fuji Pharma Co., Ltd.

4554.T

Latest Trade

1,403.00JPY

Change

11.00(+0.79%)

Volume

17,400

Today's Range

1,398.00

 - 

1,411.00

52 Week Range

1,226.00

 - 

1,927.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,392.00
Open
1,399.00
Volume
17,400
3M AVG Volume
0.48
Today's High
1,411.00
Today's Low
1,398.00
52 Week High
1,927.00
52 Week Low
1,226.00
Shares Out (MIL)
31.15
Market Cap (MIL)
43,849.08
Forward P/E
15.30
Dividend (Yield %)
2.07

Next Event

Fuji Pharma Co Ltd Annual Shareholders Meeting

Latest Developments

More

Fuji Pharma Co Says To Form Capital Tie-Up With Taiwan's Lotus Pharmaceutical

Fuji Pharma Co Ltd - Agrees To Invest $50 Million In Luxembourg-Based Alvotech Hd

Mithra Pharmaceuticals signs license and exclusive supply agreement with Fuji Pharma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

Industry

Biotechnology & Drugs

Contact Info

6F, Seito Kaikan, 5-7, Samban-cho

+81.3.35563344

http://www.fujipharma.jp

Executive Leadership

Hirofumi Imai

Chairman of the Board, Representative Director

Takayuki Iwai

President, Chief Director of Research Development, Representative Director

Takayuki Kasai

Vice President, Manager of Toyama Factory, Director

Satoru Hiromi

Managing Director, Executive Officer, Toyama Plant Manager, Director of Quality Management

Seiichi Inoue

Managing Executive Officer, Chief Director of Corporate, Director

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

441.260

2018

112.680

2019

97.040

2020(E)

91.700
Price To Earnings (TTM)
14.41
Price To Sales (TTM)
1.21
Price To Book (MRQ)
1.11
Price To Cash Flow (TTM)
8.61
Total Debt To Equity (MRQ)
27.73
LT Debt To Equity (MRQ)
19.17
Return on Investment (TTM)
6.56
Return on Equity (TTM)
5.20

Latest News

Latest News

BRIEF-Mithra Pharmaceuticals signs license and exclusive supply agreement with Fuji Pharma

* SIGNS LICENSE AND EXCLUSIVE SUPPLY AGREEMENT WITH FUJI PHARMA FOR DONESTA IN JAPAN AND ASEAN

BRIEF-Mithra Pharmaceuticals signs binding term sheet with Fuji Pharma to commercialize Donesta in Japan and ASEAN

* Announced on Wednesday signing of a binding term sheet with the Japanese leader in women's health Fuji Pharma to commercialize Donesta in Japan and ASEAN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up